Yih-Leong Chang Selected Research

collapsin response mediator protein-1

1/2012	Phosphorylation of LCRMP-1 by GSK3β promotes filopoda formation, migration and invasion abilities in lung cancer cells.
8/2011	The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1.
1/2010	Long form collapsin response mediator protein-1 (LCRMP-1) expression is associated with clinical outcome and lymph node metastasis in non-small cell lung cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yih-Leong Chang Research Topics

Disease

66	Neoplasms (Cancer) 01/2021 - 03/2002
33	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2002
25	Adenocarcinoma of Lung 01/2021 - 09/2005
25	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2020 - 08/2005
14	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2007
11	Adenocarcinoma 01/2020 - 03/2002
8	Carcinoma (Carcinomatosis) 08/2020 - 01/2011
5	Sarcoma (Soft Tissue Sarcoma) 04/2016 - 05/2014
4	Disease Progression 03/2020 - 08/2005
4	Esophageal Squamous Cell Carcinoma 08/2019 - 07/2008
4	Colorectal Neoplasms (Colorectal Cancer) 07/2015 - 01/2012
4	Lymphatic Metastasis 08/2014 - 01/2010
3	Thymoma (Thymic Carcinoma) 01/2022 - 02/2010
3	Squamous Cell Carcinoma of Head and Neck 12/2020 - 02/2004
3	Malignant Pleural Effusion 01/2019 - 06/2012
3	Nasopharyngeal Carcinoma 01/2017 - 05/2008
3	Lymphoma (Lymphomas) 01/2016 - 05/2008
3	Necrosis 01/2016 - 03/2006
2	Vasculitis (Vasculitides) 02/2022 - 12/2002
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2016 - 08/2005
2	Melanoma (Melanoma, Malignant) 01/2016 - 01/2016
2	Hypoxia (Hypoxemia) 01/2016 - 11/2015
2	Mouth Neoplasms (Oral Cancer) 01/2016 - 02/2004
2	Inflammation (Inflammations) 06/2015 - 10/2013
2	Goiter 01/2014 - 03/2006
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2011 - 06/2005
2	Teratoma (Teratoid Tumor) 04/2010 - 11/2006
1	Pemphigus (Pemphigus Vulgaris) 05/2022
1	Papillomavirus Infections 03/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2022
1	Breast Neoplasms (Breast Cancer) 02/2022

Drug/Important Bio-Agent (IBA)

34	ErbB Receptors (EGF Receptor)IBA 03/2020 - 02/2006
19	Tyrosine Kinase InhibitorsIBA 01/2021 - 12/2008
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2004
12	ParaffinIBA 03/2017 - 10/2005
8	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2010
8	DNA (Deoxyribonucleic Acid)IBA 02/2022 - 01/2007
8	Messenger RNA (mRNA)IBA 01/2019 - 08/2005
6	Anaplastic Lymphoma KinaseIBA 01/2020 - 05/2014
6	Gefitinib (Iressa)FDA Link 01/2015 - 09/2005
5	Indicators and Reagents (Reagents)IBA 03/2022 - 03/2002
5	AntibodiesIBA 01/2016 - 06/2005
4	LigandsIBA 12/2020 - 05/2014
4	Cadherins (E-Cadherin)IBA 01/2019 - 03/2002
4	Pemetrexed (MTA)FDA Link 09/2017 - 06/2011
4	Protein Isoforms (Isoforms)IBA 01/2013 - 08/2005
3	Phosphotransferases (Kinase)IBA 01/2021 - 01/2012
3	pembrolizumabIBA 08/2020 - 01/2017
3	B7-H1 AntigenIBA 01/2020 - 12/2017
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 05/2011
3	Thymidylate SynthaseIBA 09/2017 - 10/2011
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2016 - 02/2004
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2014 - 01/2012
3	collapsin response mediator protein-1IBA 01/2012 - 01/2010
2	Immunoglobulin G (IgG)IBA 05/2022 - 10/2006
2	PlatinumIBA 01/2022 - 03/2017
2	brigatinibIBA 01/2021 - 01/2020
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2020 - 05/2011
2	CrizotinibIBA 01/2020 - 01/2020
2	osimertinibIBA 01/2019 - 01/2018
2	AntigensIBA 12/2017 - 06/2005
2	Small Interfering RNA (siRNA)IBA 09/2017 - 03/2007
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 07/2017 - 01/2016
2	MicroRNAs (MicroRNA)IBA 01/2017 - 01/2013
2	Epidermal Growth Factor (EGF)IBA 10/2016 - 09/2007
2	Phosphatidylinositols (Phosphatidylinositol)IBA 04/2016 - 01/2016
2	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2016 - 03/2014
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 01/2016
2	VimentinIBA 08/2015 - 08/2011
2	CateninsIBA 08/2014 - 03/2002
2	Biological ProductsIBA 08/2011 - 10/2005
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2007 - 11/2006
2	Estrogen Receptor alphaIBA 10/2005 - 10/2005
2	Estrogen Receptor betaIBA 10/2005 - 10/2005
1	AutoantibodiesIBA 05/2022
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 05/2022
1	Interleukin-8 (Interleukin 8)IBA 05/2022
1	Immunoglobulin A (IgA)IBA 05/2022
1	human ERBB2 proteinIBA 02/2022
1	pertuzumabIBA 02/2022
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 02/2022
1	trastuzumab deruxtecanIBA 02/2022
1	Ado-Trastuzumab EmtansineIBA 02/2022
1	Trastuzumab (Herceptin)FDA Link 02/2022
1	Lapatinib (GW572016)FDA Link 02/2022
1	Dynamins (Dynamin)IBA 01/2021
1	Mitochondrial DNA (mtDNA)IBA 01/2021
1	Serine (L-Serine)FDA Link 01/2021

Therapy/Procedure

19	Therapeutics 02/2022 - 04/2003
14	Drug Therapy (Chemotherapy) 01/2022 - 06/2005
8	Immunotherapy 01/2020 - 05/2014
7	Radiotherapy 01/2016 - 11/2006
4	Thoracotomy 04/2010 - 10/2008
3	Adjuvant Chemotherapy 08/2014 - 11/2006
2	Induction Chemotherapy 11/2019 - 08/2019
2	Esophagectomy 08/2019 - 04/2015
2	Aftercare (After-Treatment) 01/2018 - 12/2008
2	Neck Dissection (Radical Neck Dissection) 06/2017 - 06/2012
2	Neoadjuvant Therapy 05/2015 - 04/2015
2	Tracheostomy 01/2014 - 11/2006